Ranbaxy launches worlds first Bio-generic recombinant injectible

Ranbaxy Laboratories has announced the launch of BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis, in collaboration with Virchow Biotech, Hyderabad, India. Ranbaxy is the first company to launch this bio generic product in the world.

The product has been indigenously researched at Virchow Biotech and developed with and from the Department of Science and Technology, Government of India. Virchow Biotech, part of the Hyderabad based Rs 600 crore Virchow Group, engages in research, development, manufacture and marketing of a wide range of unique classical biologicals and high value recombinant bio-generie products for serious life-threatening diseases at affordable prices.